Johnson & Johnson

$145.18

+1.25 (+0.01%) Today
1 Day1D

5 Days5D

1 Month1M

6 Months6M

YTDYTD

1 Year1Y

2 Years2Y

5 Years5Y

MaxMax

About

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

CEO

Alex Gorsky

Employees

132200

Headquarters

One Johnson & Johnson Plaza New Brunswick, NJ, 08933

Founded

1886

Market Cap

Johnson & Johnson News

Diversity in medtech: Just 20% of executive roles held by women Oct 13, 2020

Diversity in executive roles in the medical device industry is trending more toward parity, with women holding 2% more C-suite roles in 2020 compared to last year. Just 20% of executives at the 100 largest medical device companies in the world are women, and those companies average 19% female composition in the C-suite, according to…

Diversity in medtech: Just 20% of executive roles held by women Oct 13, 2020

Diversity in executive roles in the medical device industry is trending more toward parity, with women holding 2% more C-suite roles in 2020 compared to last year. Just 20% of executives at the 100 largest medical device companies in the world are women, and those companies average 19% female composition in the C-suite, according to…

J&J halts COVID-19 vaccine trial due to illness Oct 13, 2020

Johnson & Johnson (NYSE:JNJ) announced that it temporarily paused further dosing in its COVID-19 vaccine candidate clinical trials. The pause in the trials conducted by J&J’s Janssen Pharmaceuticals subsidiary follows an unexplained illness arising in a study participant, according to a news release. Under the company’s guidelines, the illness is being reviewed and evaluated by internal…

Vaccine trial pause sees Johnson & Johnson dip despite strong Q3 Oct 13, 2020

Johnson & Johnson (NYSE:JNJ) shares ticked down despite third-quarter results that came in well ahead of the consensus forecast. News of the company’s COVID-19 vaccine candidate trial being put on pause after a patient illness likely played its part, as shares of JNJ were trading down -2.1% at $148.68 per share in midday trading today. The […]

J&J halts COVID-19 vaccine trial due to illness Oct 13, 2020

Johnson & Johnson (NYSE:JNJ) announced that it temporarily paused further dosing in its COVID-19 vaccine candidate clinical trials. The pause in the trials conducted by J&J’s Janssen Pharmaceuticals subsidiary follows an unexplained illness arising in a study participant, according to a news release. Under the company’s guidelines, the illness is being reviewed and evaluated by internal and independent […]